Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like the drugs that the company is trying to produce. I think the company has great potential.
I think management has been absolutely pathetic on no update after a major loss to shareholders. One month later and not one word, no guidance, no nothing.
Is this going to take a year or another month?
Is it not us that pays their salary and is entitled to some kind of word on what is going on? Stop the bleeding by some guidance. I have never seen a major company that never said a word after this kind of lossto its shareholders.
Boing X 2
New pre grant patent application,
METHODS RELATED TO BIOLOGICS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=5&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"
[0030] Detailed, high resolution, physiochemical and/or structural information about Actemra.RTM. (e.g., related to the presence of signature glycan species or quantitative analyses ascribing site-specificity for backbone modifications) can be used in the manufacture of products that qualify as tocilizumab, e.g., that are interchangeable versions of Actemra.RTM.. Such information is also useful in monitoring product changes and controlling structural drift that may occur as a result of manufacturing changes. One exemplary report states that "[t]he size and complexity of . . . therapeutic proteins make the production of an exact replica almost impossible; therefore, there are no true generic forms of these proteins . . . . Verification of the similarity of biosimilars to innovator medicines remains a key challenge." (Hincal et al "An Introduction To Safety Issues In Biosimilars/Follow-On Biopharmaceuticals", J. Med. CBR Def, 7:1-18, (2009)). This disclosure provides, in part, methods and compositions sufficient to make and test products that qualify as tocilizumab, e.g., that are interchangeable versions of Actemra.RTM.. “
Boing X 2
First that I heard of this one.
http://www.biopharminternational.com/momenta-receives-warning-letter-generic-copaxone
"Meanwhile, on Feb. 16, 2017, a day before Momenta formally recognized the warning letter, Pfizer CentreOne announced it has expanded its fill/finish capabilities to its Kalamazoo, MI site. The site will now handle sterile injectables.
Source: Momenta"
This brings up a lot of interesting question. Does Pfizer owe us an obligation to get the 40mg Glatopa approved and manufactured at the MI plant if they can’t get approval, at the Kansas plant, for months yet. Apparently the MI plant has the ok for production of sterile injectables..
How hard would it be for Pfizer to tell the FDA that the 40mg Glatopa would be manufactured there while they work out the Kansas problems.
Note the PR.
https://www.pfizercentreone.com/news/contract-manufacturer-pfizer-centreone-expands-fill-finish-services-its-kalamazoo-michigan
Why did I have to scour the net to find out about this blurb? Why is Momenta not pushing hard on Sandoz and Pfizer to do this.
Pfizer is costing us all big bucks and this should be a no brainer to cut our losses since they have a new plant with the capacity and should give us priority so we can get the FDA approval.
Not sure if the FDA could hold us hostage on approval because of Pfizers problems if they tell them they will manufacture at the new plant.
How about this as an option? Manufacture at the new plant. Momenta is aware of this MI plant based on the PR. I know Sandoz and Pfizer control but, they should not control to the detriment of our FDA approval by not mfg. at a new plant.
It would seem that after 18 days that is what we should be hearing is going to be being done or if not why not. Days count big time on all our losses. It would take one day to let the FDA know they are switching to the approved plant. That would take us out of the twilight zone here.
There might be reasons why they can’t, but. no one is telling us why not.
Boing X 2
New pre grant patent application,
COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"XIII. Indications
[0141] The pharmaceutical compositions and methods of the invention are useful to reduce inflammation in a subject, to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to reduce the immune response, e.g., to block immune complex-based activation of the immune response in a subject, and to treat immunological and inflammatory conditions or diseases in a subject. Exemplary conditions and diseases include rheumatoid arthritis (RA); systemic lupus erythematosus (SLE); ANCA-associated vasculitis; antiphospholipid antibody syndrome; autoimmune hemolytic anemia; chronic inflammatory demyelinating neuropathy; clearance of anti-allo in transplant, anti-self in GVHD, anti-replacement, IgG therapeutics, IgG paraproteins; dermatomyositis; Goodpasture's Syndrome; organ system-targeted type II hypersensitivity syndromes mediated through antibody-dependent cell-mediated cytotoxicity, e.g., Guillain Barre syndrome, CIDP, dermatomyositis, Felty's syndrome, antibody-mediated rejection, autoimmune thyroid disease, ulcerative colitis, autoimmune liver disease; idiopathic thrombocytopenia purpura; Myasthenia Gravis, neuromyelitis optica; pemphigus and other autoimmune blistering disorders; Sjogren's Syndrome; autoimmune cytopenias and other disorders mediated through antibody-dependent phagocytosis; other FcR-dependent inflammatory syndromes e.g., synovitis, dermatomyositis, systemic vasculitis, glomerulitis and vasculitis. “
Boing X 2
jborg,
"Everything you say is fine, but the main point is that the manufacture, sales and distribution of Glatopia is Sandoz's responsibility. Momenta has zero to none involvement at this level.”
I agree, except, they have a responsibility to make sure of what is going on, what they are doing and how it might impact them.
"I'd have to assume that there is a joint management team consisting of Sandoz and Momenta personnel to make any decisions. The problem would be that Sandoz would carry a stronger vote.”
True, but that does not stop Momenta from recognizing any potential problems and recognize any risk and make an informed decision how to handle them, as far as Momenta shareholders, should anything go wrong.
"Let's understand one thing, Momenta contracts to its customer which is Sandoz. Momenta has no relationships with the Pharmacies or Customers. Momenta has no relationship to Pfizer”
I will accept that. Then Sandoz should be speaking up. It still does not relieve Momenta of having everything covered with Sandoz or, determining if there is an insurable problem should Sandoz be unable to perform, as far as
Momenta shareholders are concerned.
That is the point I am trying to make. It takes risk management to Identify potential problem areas, Determine potential exposure and alternatives, Identify potential solutions and implement solutions and then control and monitor the results.
So far no word from Momenta on the problems so we know nothing.
Boing X 2
jbog,
No I am not getting Sandoz and Pfizers responsibilites confused. If you see I said both Pfizer and Sandoz has that responsibility at the end of my post. As far as I am concerned they owe us shareholders some explantation either through them or Momenta.
I am saying we should have a risk manager on board or hire one for input of a risk assessment to determine Momenta's risk potentials. i.e. business interruption would likely cover a problem with Glatopa 20mg but I doubt not the 40mg without an FDA approval and the start of manufacturing.
Risk Management would identify all Momenta's potentials for exposures and make a conscious decision to insure or self insure or get indemnity agreements if someone else messes up.
Like I say, what if they have a Kansas tornado and we are out of business for a year. Momenta needsback up plans ready to implement on a moments notice if Sandoz or Pfizer can't perform. We don't have the luxury of waiting a year here and there.
Boing X 2
randychub,
Glad you asked. I have revised this so many times but here goes.
I for one am disappointed at the long silence.
Momenta has not seen fit to give any kind of an update to the shareholders. I don’t consider them their attending a Cowan conference the same an an update to shareholders after our shock loss. PFE and Sandoz have been quiet likewise.
If they can’t give us an update yet, say so and give us an idea when they can.
I still want to know when they first became aware of the problems. June of last year or when? It is going to come out sooner or later.
The full FDA letter is out there and I am not as optimistic things can be corrected so fast with a fast FDA approval. We don’t have Momenta’s input on their feeling yet. Surely they have had numerous discussions with PFE and Sandoz by now.
Per the FDA letter,
"These repeated failures at multiple sites demonstrate that your company’s oversight and control over the manufacture of drugs is inadequate.” and ''You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems and processes, and ultimately, the products manufactured, conform to FDA requirements.” Have they done this since June? Don’t know yet. Don’t know how far along they are yet. Bringing people into one site for a quick fix doesn’t sound like a correction of a global problem that will get the FDA approval. I guess they
could give piecemeal approval but, it doesn’t sound like they are after that kind of approval.
Did we not have some kind of cooperation deal with WuXi for potential drug manufacture not too long ago. I just could not find the PR. If I remember right they even opened an office in Cambridge to be close to Momenta. I am aware they were taken private.
I see they opened a plant in PA not long ago. They were building a new plant in Shanghai. The PA plant appears to be in compliance right now as well as the one in Shanghai.
It would seem that Momenta needs to assure with the manufacture or manufactures, in the future, that there has to be a back up system in place should this problem arise again. It is called Risk Management. What if the Pfizer plant has a fire or a tornado or another warning letter. Will we have to wait months for repairs, with major losses, before they can produce our drug again?
Not acceptable. Momenta should consider adding a risk manger if they don’t have one or hire a risk management firm to identify the companies potential risks. The Risk Manager should make sure their are back up plants in place with FDA approved plants that can take over on short notice. Just my thoughts. I don’t want to be going through this ever again. Momenta just develops the drugs so they have to make sure they are protected from this kind of exposure in the future.
Sandoz and Pfizer as big as they are, should have had these contingency plans in place. A risk manager could have made sure those plans were in place or have indemnity agreements should they not be in place.
Not a I’m sorry to the Momenta shareholders by either Sandoz or Pfizer to this point.
Boing X 2
New patent application,
METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF KAWASAKI DISEASE
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
IVIG
Boing X 2
New patent application
HIGH MANNOSE GLYCANS
https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20170217&CC=ES&NR=2602108T3&KC=T3
Boing X 2
My take after dwelling on the news last night.
A question I have is Scott’s presentation that all appeared to be on track for approval. Two days later not so. I would be steamed, if I were him, about my reputaion and be asking Momenta if they had any the warnings about the problem.
Nest question I have would be was Momenta aware of prior FDA warning of issues as some indicate they give warnings before the letter.
If they were not, why not? That could be a problem for Pfizer if they had not made us aware of prior warnings. Doing a google search they have had a lot of warnings on other drugs. PFE should well be aware of the standards to avoid this kind of problem.
If they made Momenta aware, then why would that not be mentioned as a potential issue prior to approval and what we were discussing with them. All the facts here are going to come out sooner or later once we find out what the FDA letter said.
Who picked PFE? Sandoz or Sandoz and us?
Next, the time frame they expect to correct the problem or problems.
Next any other possible alternatives to speed things up towards approval.
Any agreements that might or might not protect Momenta its shareholders for this delay. I would guess we suffer delay of potential large earned payments and therefore resulting lack of interest earned due to the lack os sales of the 40mg Glatopa drug.
We know there are multiple calls to out right buy our M923. hsIvig is in the wings along with other drugs. I am hanging tight waiting on the CC along with taking a deep breath.
Now is the time for straight clear answers as they know the facts.
Boing X 2
t57,
I forgot to add this is another reason I think Momenta is smart to just discover and develop the drugs and leave the Mfg. production and sales to others. Many less headaches.
Here is hoping there is no agreements to prevent recovery for our damages.
Of note, PFE had no PR on the failure to comply, that I could find, yesterday.
Boing X 2
t57,
Great question that should be answered on the CC.
I am not a sue type of guy but, in this instance loss of180 day exclusivity is a major damage to the shareholders. Also, a further loss of profits until approval.
If there are no agreements stating otherwise, that we can't recover damages, Momenta needs to try and recover damages for the shareholders.
There would have to be no damages on the 180 day exclusivity if no other product is approved within 180 days from the time we get FDA Approval.
There would still be damages from the delay they caused until approval.
Hopefully they answer these questions on the CC. Just all IMHO.
Boing X 2
DewDiligence,
Thank you for your feedback. It is appreciated very much.
Boin x 2
DewDiligence,
Do you have an educated estimate of what kind of offer would be made by multiple parties to outright buy our drug. I go for the partnering as I have stated.
Would the offer be based on a percent of the total sales or a percent of some portion of the total. Any idea?
14 billion in sales a year for Humira.
Boing X 2
floblu14,
Thank you for this important information.
I think MNTA would be smart to do a deal and leave the production headaches and sales force headaches to the partner.
Just keep on developing more drugs, do more deals and rake in more money. Ever increasing cash flow to the coffers. Just my opinion.
Boing X 2
Quite interesting.
Also, thank you to all for the feedback on the cc as I could not get the audio to work. I guess they don’t realize millions of us have Apple Safari and not the other options.
http://www.nasdaq.com/symbol/mnta/institutional-holdings
This only covers to year end and not if 4.6M shorts covered in Feb. Ownership jumped over 1 percent from yesterday when I checked. End of year filings updated last night.
6422000 less 4600000 shorts, provided shorts covered, leaves 1822000 shares to the public per my calculator. Subtract individual investors and 179 institutions can suck the remaining shares up in several days.
IMHO something is going to have to give shortly. Tonight the shorts report and we will know on the 27th how many covered or not by the 15th. If they have been adding institutional shares at 1M a month it is not hard to see what is happening.
The general public is likely to have to pay dearly for our stock once the FDA approval is issued.
Institutional Ownership 90.56%
Total Shares Outstanding (millions) 71
Total Value of Holdings (millions) $1,230
Active Positions
HOLDERS SHARES
Increased Positions 83 7,872,611
Decreased Positions 61 4,039,147
Held Positions 35 52,667,240
Total Institutional Shares 179 64,578,998
New and Sold Out Positions
Total ActiveShares
New/SoldShares
-5M
0M
5M
10M
HOLDERS SHARES
New Positions 25 4,194,668
Sold Out Positions 18 1,785,83
Second article today by a different writer.
"http://finance.yahoo.com/news/forget-gilead-buy-5-biotech-141402577.html"
Boing X 2
Sorry about the extra posts. Hit submit and would not go through.
We might get some answers on the 15th. I am sure the question will be asked.
Upcoming Events
Date Details Remind Me
Feb 15, 2017
10:30 AM ET
Leerink Partners 6th Annual Global Healthcare Conference
Listen to webcast
Boing X 2
Nice,
Hope they are right on Momenta comments.
"http://finance.yahoo.com/news/5-stocks-buy-trump-chalks-135301352.html"
Boing X 2
Full Disclosure
Just found this.
My family owns this dot.com. It covers all combinations of the letters hsivig.com and Momenta hsivig.com.
We did not order this to be set up. It appears someone else might see the potential of hsivig.com to go to the expense and time to set this up.
Interesting to say the least ,as, I doubt someone would go to the expense to do this for every single dot.com that might never take place.
http://site-assay.com/site/hsivig.com
Just being up front and letting all know before someone else finds and posts it. Bought them when I saw they were not taken. Might take years, but I am patient.
Boing X 2
DewDillegence,
Thank you for the ariticle.
Throw in these two
"Anti-Inflammatory Therapeutics Market
Anti-Inflammatory Therapeutics Market Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells ... Published Date:
Sep 2015 Price:
$4740(SU)
Biosimilars Market
Biosimilars Market Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of ..."
and we have some pocket change to go after.
Boing X 2
jborg
I admit I was wrong about Necuparanib but, I never said it was worth billions. I believed what had been told on results at the time and the slides did show improvement. I would have no way of knowing without them saying they say a problem. I honestly did believe they were getting top line results. There were no warnings otherwise until they dropped it.
Watson Pharmaceuticals, or who owns them now, is most likely on the hook, if Amphastar looses and can't pay it all.
The ruling was they violated the Wax Hatchman statute on our patent.
Boing X 2
jbog,
And Amphastar has a good chance of paying very dearly for doing it to MNTA. Time will tell.
As things currently stand, you fail to mention that big fact on the current status of litigation. It might change, but then again they might well pay us big time. They have nice back up to foot the huge bill they might well face.
The facts are in our favor, right now, and you fail to mention that. Why would you even bring this up except to put MNTA down.
If you are going to keep putting MNTA down, give the total facts. THEY RULED THAT THAT THEY VIOLATED OUR PATENT. Until that changes we are in the drives seat.
Boing X 2
indigokid,
Thank you for that feedback.
Boing X 2
indigokid,
You are welcome. Just my guess on putting a pencil to what I feel can happen.
I note last quarter we were -.26 cents a share and with whisper numbers showing around .23 cents this quarter. That means we should break into the black this next quarter or close to it.
I think we are looking pretty strong on a down day. Keeps clawing its way back up.
You might be more right than me and I hope you are. At any rate, we should be in the black next year.
I feel still way under valued for what is in the works compared to some other stocks. Time will tell.
Now we just need that approval.
Boing X 2
indigokid,
I forgot to add,
there should be a substantial reduction in costs of syringes per patient reducing the number from 365 a year to 156 a year. That is a reduction of 209 syringes per patient a year with the 40mg. approval. That is a substantial number if talking about each 1,000 patients.
I am not sure as to how much more it costs to produce 40mg vs. 20mg. Glatopa but, there should be an economy of scale on production.
Boing X 2
indigokid
Great posts by all while I was gone. FDA has my approval to give approval today.
Sorry for the delay in response.
I based my estimate of 6K cost per quarter. While I was estimating 50M cost of production and sales costs. A margin of 66.33% While that might sound high it might not be as they already have the production in place, there should be less legal expense on this launch. The margins should go up as they are not having to convince every doctor this go around.
Like I said, others can play with the numbers.
It was great to see the pop while on the high seas. It took me a while to ready through all the posts this am.
Boing X 2
One other statistic,
In the United States, about 200 new cases of MS are diagnosed each week.
Boing X 2
The Sky is falling, The Sky is falling,
Total number of people worldwide with multiple sclerosis is 2.5 million. Number of people in the US with multiple sclerosis is 400,000. I suspect these are older figures.
We have 42% of the 20mg Copaxone market. I suspect they will convert those scripts to 3X a week 40mg Glatopa.
Approval of Glatopa 40mg is shortly going to take care of our quarterly expenses and likely then some. We are earning 20M a quarter now.
We only need to get to 50M a quarter to break even and cover overhead, salaries and research.
I estimate it will take us a total of 25,000 scripts a quarter to get us to our share of 50M after sales costs, and Novartis 50% profit, at 6,000 a script per quarter.That would be 500 or so scripts per state we need.
Right now I am seeing 2,500 a month as the lowest monthly cost for 30 shots for the 20mg. For the sake of this example I am using a 6k quarterly number.
Double it to 1k scripts per state should be more than doable. It would be nice if we knew the number of scripts the 42% of 20mg injections represents right now.
I frankly think Teva is very worried that we are going to take way more than 1k scripts per month per state average, They would probably be very happy with us taking that few.
Play with the script numbers and it is not going to take us long. I don’t see future dilution if we exceed 25,000 scripts per quarter. Again, that is only 500 per state per quarter or 166.66 per month per state. That would be 8,333 people with monthly scripts out of 400,000 people.
Like Craig said, we hold a lot more cards on a 40mg approval. I can see pharmacies directing that many scripts to us.
There are 67,000 pharmacy’s in the US and the top six have this many pharmacists. 2nd number is the number of stores. CVS 25,436 pharmacist filling one script each would do it.
CVS Corporation Woonsocket RI 24,000 9,700
2 Walgreens Deerfield IL 10,578 8,232
3 Walmart Stores Inc Bentonville AR 6,358 3,646
4 Rite Aid Corporation Camp Hill PA 5,523 4,608
5 Kroger Company Cincinnati OH 1,866 1,156
6 Target Corporation now CVS Pharmacy Minneapolis MN 1,436 1,672
Other drugs will likely be kicking in, prior to any future dilution, IMHO. With a shorter process to FDA approval I think we are going to be alright.
I will not even discuss on how undervalued I think we are right now. Look at Blue for a clue.
With all this being said, Wed. we are heading out of the country on a two week cruise to where it is warm. I am hoping to see approval come in while we are on the high seas. I will be watching the net.
Ciao,
Boing X 2
DewDiligence,
I agree.
A couple of thoughts,
I think this is critical wording to avoid the games of sales reps telling the doctors to write a script DAW {drawn as written) to keep competition away.
"57 351(k)(4) of the PHS Act, means that “the biological product may be substituted for the
58 reference product without the intervention of the health care provider who prescribed the
59 reference product.”6
"134 An interchangeable product may be substituted for the reference product without the intervention
135 of the health care provider who prescribed the reference product "
I have seen comments by sales reps doing that exact thing and joking about it on line. Keeping sales away from us by telling the doctor’s to write the script DAW so the pharmacist can’t change it.
I would get the patent to cover either way of injection. Doesn’t mean you have to do it but, it would keep others from saying well they didn’t cover auto injector. Amphastar comes to mind on an end around.
"A sponsor developing an
654 interchangeable product generally should not seek licensure for a presentation for which the
655 reference product is not licensed. For example, if the reference product is only marketed in a
656 vial and a prefilled syringe, a sponsor should not seek licensure for the proposed interchangeable
657 product for a different presentation, such as an auto-injector."
Boing X 2
indigokid,
You might well be right. It caught me off guard.
No matter which drugs ,they are thinking big.
Throw in Express Scripts while they are at it.
Boing X 2
Bickema;
Craig mentioned about the potential to contract with them selling the generic 40mg Capxone along with the 20mg.
Boing X 2
Bickema,
Right you are.
Another comment, about CVS and Walgreens about blew me out of my chair.
Boing X 2
Bickema,
I agree.
I see more and more potential with this company and how they are proceeding.
I like how Craig said we hold a lot of cards for the 40mg launch that we did not hold on the 20mg launch of Copaxone.
Boing X 2
Least anyone forgot,
" Craig Wheeler, President and CEO, will present at the 35th Annual J. P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 10th at 3:00 p.m. PT (6:00 p.m. ET).
Following the presentation, management will participate in a question and answer session at 3:30 p.m. PT (6:30 p.m. ET).
The webcast of the presentation and Q&A session will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event."
It would be nice to hear something about 40mg Glatopa.
Boing X 2
Breakout trade
"WATCH for possible breakout above 16.68
Target: 18.1,"
Just found this from this morning,
"Momenta Pharmaceuticals's buy rating reiterated at Stifel Nicolaus. $20."
Nice little Birthday present this Sunday AM.
Boing X 2
Dew,
Thank you. I thought likely.
The thing that was throwing me off was the three momentas in the parser.
Boing X 2
Possible new pre grant patent application
BIOLOGICAL CHARACTERIZATION OF A GLATIRAMER ACETATE RELATED DRUG PRODUCT USING MAMMALIAN AND HUMAN CELLS
Before you click, prepare your mind for a wall of text. Mind boggling.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
[0009] Copaxone.RTM. also increases the number and suppressive capacity of CD4+CD25+FOXP3+ regulatory T cells, which are functionally impaired in MS patients (29-31). Furthermore, treatment leads to antigen-nonspecific modulation of APC function. Copaxone.RTM. treatment promotes development of anti-inflammatory type II monocytes characterized by an increase in interleukin (IL)-10 and transforming growth factor-beta (TGF-.beta.) and decreased production of IL-12 and tumor necrosis factor (TNF) (32).
I am not sure but, I think it might be Momenta based on the three momentas at the end of the parser. momenta&OS=momenta&RS=momenta On the other hand where some of the applicants are from, makes me wonder.
Any feedback would be appreciated. I should have got my cup of coffee first. Boy that hurts trying to read this.
Boing X 2
Breakout trade
"CONFIRMED breakout above 15.59
Target: 17.04"
Boing X 2